E-Scopics Announces New FDA Clearance for Hepatoscope® With Expanded Capabilities in Managing Liver Disease Complications, Advanced Elastography Imaging Features, and Improved Compatibility to Be Presented at DDW 2026

on

E-Scopics received U.S. FDA clearance for new enhancements to its Hepatoscope® platform, including a dedicated spleen exam workflow with real-time 2D transient elastography imaging.12

Hepatoscope achieves full compliance with the international IEC 63412-1 standard for tissue stiffness mapping, enabling better visualization of liver stiffness changes for treatment monitoring.1

New features include compatibility with macOS-based laptops and HL7® FHIR® R4 standard for direct connectivity to electronic health record (EHR) systems, reducing administrative burden.1

These advanced capabilities position Hepatoscope as the first ultraportable solution with real-time ultrasound and tissue elasticity imaging for liver and spleen assessment at the point of care.1

The enhancements will be presented at Digestive Disease Week® (DDW) 2026 in Chicago, IL, June 3-5, booth #2039.1

Sources:

1. https://www.businesswire.com/news/home/20260501601694/en/E-Scopics-Announces-New-FDA-Clearance-for-Hepatoscope-With-Expanded-Capabilities-in-Managing-Liver-Disease-Complications-Advanced-Elastography-Imaging-Features-and-Improved-Compatibility-to-Be-Presented-at-DDW-2026

2. https://app.dealroom.co/news/feed/e-scopics-hepatoscope-gains-fda-clearance-for-spleen-exam-workflow-and-advanced-elastography-imaging